-
4
-
-
0027315339
-
-
E. R. Rimm, M. J. Stampfer, A. Ascherio, E. Giovannucci, G. A. Colditz, W. C. Willett, N. Engl. J. Med. 1993, 328, 1450;
-
(1993)
N. Engl. J. Med
, vol.328
, pp. 1450
-
-
Rimm, E.R.1
Stampfer, M.J.2
Ascherio, A.3
Giovannucci, E.4
Colditz, G.A.5
Willett, W.C.6
-
5
-
-
0027154706
-
-
M. Stampfer, C. Hennekens, J. Manson, G. Colditz, B. Rosner, W. Willett, N. Engl. J. Med. 1993, 328, 1444;
-
(1993)
N. Engl. J. Med
, vol.328
, pp. 1444
-
-
Stampfer, M.1
Hennekens, C.2
Manson, J.3
Colditz, G.4
Rosner, B.5
Willett, W.6
-
7
-
-
0034708384
-
-
R. K. Unrig, M. A. Picard, K. Beyreuther, M. Wiessler, Carbohydr. Res. 2000, 325, 72;
-
(2000)
Carbohydr. Res
, vol.325
, pp. 72
-
-
Unrig, R.K.1
Picard, M.A.2
Beyreuther, K.3
Wiessler, M.4
-
8
-
-
0034898253
-
-
T. Satoh, H. Miyataka, K. Yamamoto, T. Hirano, Chem. Pharm. Bull. 2001, 49, 948.
-
(2001)
Chem. Pharm. Bull
, vol.49
, pp. 948
-
-
Satoh, T.1
Miyataka, H.2
Yamamoto, K.3
Hirano, T.4
-
10
-
-
0026795613
-
-
A. Abo, A. Boyhan, I. West, A. G. Thrasher, A. W. Segal, J. Biol. Chem. 1992, 267, 16767.
-
(1992)
J. Biol. Chem
, vol.267
, pp. 16767
-
-
Abo, A.1
Boyhan, A.2
West, I.3
Thrasher, A.G.4
Segal, A.W.5
-
12
-
-
34248546702
-
-
Spectral data for selected products; product 3: HR-FAB-MS: m/z 777.4770 [M, Na, 1H NMR (400 MHz, CD 3OD, δ 0.86 (6H, d, J, 6.8 Hz, 13, 17-CH 3, 0.87 (6H, d, J, 6.8 Hz, 21-CH3, H-22, 1.06-1.53 (21H, m, H-10, 11, 12. 13, 14, 15, 16, 17, 18, 19, 20, 21, 1.22 (3H, s, 1-CH3, 1.80 (2H. m, H-2, 2.05 (3H, s, 5-CH3, 2.17 (3H, s, 8-CH3, 2.21 (3H, s, 7-CH3, 2.58 (2H, m, H-3, 3.14-3.53 (8H, m, H-2′, 2″, 3′. 3″, 4′, 4″, 5′, 5″, 3.64 (1H, dd, J =12.0, 5.4 Hz, H-6a″, 3.74 (1H, dd, J, 12.0, 5.2 Hz, H-6a′, 3.84 (1H, dd, J, 12.0, 1.2 Hz, H-6b″, 4.03 (1H, dd, J, 11.2, 1.2 Hz, H-6b′, 4.23 (1H, d, J, 7.6 Hz, H-1″, 4.52 (1H, d, J, 7.6 Hz, H-1′, 13C NMR (100 MHz, CD3OD, δ 12.2 5-CH3, 1
-
3), 25.4 (C-15), 25.9 (C-19), 29.2 (C-21), 32.8 (C-2), 33.8 (C-13, C-17), 38.6 (C-12, C-14, C-16, C-18), 40.5 (C-20), 41.1 (C-10), 62.7 (C-6″), 68.5 (C-6′), 71.7 (C-4′), 72.0 (C-4″), 72.8 (C-5″), 73.4 (C-2″), 73.7 (C-3″), 75.2 (C-2′), 75.8 (C-1), 76.4 (C-3′), 77.9 (C-5′), 100.4 (C-1′), 106.0 (C-1″), 118.6 (C-4), 123.4 (C-5), 127.7 (C-7), 129.6 (C-8), 147.3 (C-6), 149.2 (C-9).
-
-
-
-
14
-
-
0025675676
-
-
A. Koda, T. Miura, N. Inagaki, O. Sakamoto, A. Arimura, H. Nagai, H. Mori, Int. Arch. Allergy Appl. Immunol. 1990, 92, 209.
-
(1990)
Int. Arch. Allergy Appl. Immunol
, vol.92
, pp. 209
-
-
Koda, A.1
Miura, T.2
Inagaki, N.3
Sakamoto, O.4
Arimura, A.5
Nagai, H.6
Mori, H.7
-
15
-
-
34248550112
-
-
Male Wistar rats, each weighing 250 to 300 g, were used. Under ether anesthesia, whole blood was collected from the carotid artery and diluted twice with Hanks' balanced salt solution (HBSS, pH 7.4, Neutrophils were purified by Percoll density gradient centrifugation. O2- generation from rat neutrophils was measured by the cypridina luciferin analog-dependent chemiluminescence method.11 An authentic antiallergic agent, mequitazine, was used as a positive control. Neutrophil suspensions (10 6 cells/mL) were incubated for 3 min in HBSS containing 0.4 mM of cypridina luciferin analog and 50 μM of α-tocopheryl glycoside or authentic antiallergic agent, which was a proper concentration for the present bioassay, at 37°C in the dark. Five seconds later, N-formyl-Met-Leu- Phe (fMLP, 2.5 μM) was added into the assay mixture. Cypridina luciferin analog-dependent chemiluminescence was monitored with a Lumicounter ATP-237 Advan
-
- generation from rat neutrophils at 5 min after the administration of fMLP by test compounds.
-
-
-
|
